Phytotherapy for the prostate

British Journal of Urology

Volumn 78, Issue 3, 1996, Pages 325-336

  Buck, A C ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOPROSTAL; ARACHIDONIC ACID; AZUPROSTAT; BAZOTEN; CERNITIN; COUMESTROL; CUCURBITACIN; CUCURBITACIN GLYCOSIDE; ESTRADIOL; ESTRIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ESTRONE; ETHINYLESTRADIOL; EVIPROSTAT; FLAVONOID; GENISTEIN; HACHIMIGIOGAN; HEWESABAL; MESTRANOL; NOMON; PHYTOESTROGEN; PLANT EXTRACT; PROSTAFORTON; PROSTAGALEN; PROSTAGUTT; PROSTASELECT; PROSTATIN; PROSTAVIGOL; PROSTITIS DRG; PYGEUM AFRICANUM EXTRACT; REMIGERON; SABALUX; SALUS CURBIS TC; SITOGLUSIDE; SITOSTEROL; STEROID 5ALPHA REDUCTASE INHIBITOR; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; URGENIN; URTICA EXTRACT; URTICA PLUS;

CARCINOGENESIS; CHEMICAL STRUCTURE; CLINICAL TRIAL; CYSTO FINK; HUMAN; MALE; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTAMED; PROSTATE HYPERTROPHY; PYGEUM; RESIDUAL URINE; REVIEW; SABAL; SYMPTOMATOLOGY; URODYNAMICS;

EID: 0030430231     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.00104.x     Document Type: Review

References (59)

1. Liang T, Liao S. Inhibition of steroid 5a-reductase by specific aliphatic unsaturated fatty acids. Biochem ] 1992; 285: 557-62
2. Schmitz W. Urologika In Arzneimittel Verdungs-Report 87. Schwabe U, Paffrath D, eds, Stuttgart: Fischer G 1987: 365-73
3. Di Silverio F, Flammia P, Sciarra A et al. Plant extracts in BPH. Minerva Ural Nefrol 1993; 45: 143-9
4. Bradbury RB, White DE. Estrogens and related substances in plants. Vit Horm 1955; 12: 207-33
5. Jordan VC, Mittal S, Gosden B, Koch R, Lieberman E. Structure-activity relationships of estrogens. Environ Health Perspectives 1985; 61: 97-110
6. Shutt DA, Cox RI. Steroid and phyto-estrogen binding to sheep uterine receptors in vitro. J Endocrinol 1972; 52: 299-310
7. Bickoff EM, Livingstone AL, Booth AN. Tricin from alfalfaisolation and physiological activity. J Pharm Sci 1964; 53: 1411-2
8. Wenzel DG, Rosenberg P. Estrogenic activity of some flavonoids. J Am Pharm Assoc Sci Ed 1956; 45: 367-9
9. Shemesh M, Lindner HR, Ayalon N. Affinity of rat uterine oestradiol receptor for phyto-oestrogens and its use in a competitive protein-binding radioassay for plasma coumesterol. J Reprod Pert 1972; 29: 1-9
10. Alcaraz MJ, Ferrandiz ML. Modifications of arachidonic metabolism by flavonoids. J Ethnopharmacol 1987; 21: 209-29
11. Mower RL, Landoff R, Steiner M. Inhibition in vitro of platelet aggregation and arachidonic acid metabolism by flavone. Biochem Pharmacol 1984; 33: 357-63
12. Welton AF, Tobias LD, Fiedler-Nagy C et al. Effect of flavonoids on arachidonic acid metabolism. Prog Clin Biochem Res 1986; 213: 231-42
13. Sweis }, Robak J, Dabrowski L, Duniec S, Michalska Z, Gryglewski RJ. Anti-aggregatory effects of flavonoids in vivo and their influence on lipoxygenase and cyclooxygenase in vitro. Polish }Pharmacol Pharm 1984; 36: 455-63
14. Baumann J, Bruchausen F, Wurm G. Flavonoids and related compounds as inhibitors of arachidonic acid peroxidation. Prostaglandins 1980; 20: 627-39
15. Middleton E Jr, Drzewiecki G. Effects of flavonoids and transitional metal cations on antigen-induced histamine release from human basophils. Biochem Pharmacol 1982: 31: 1449-53
16. Delia Loggia A. Tubaro A. Dri P. Zilli C. Del Negro P. The role of flavonoids in the anti-inflammatory activity of Chamomilla n'cutita. Prog Clin Biochem Res 1986: 213: 481-4
17. Gryglewski RJ, Korbut R. Robak J, Sweis J. On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 1987: 36: 317-22
18. Cerutti PA. Peroxidant states and tumour promotion. Science 1985: 227: 375-81
19. Kato R, Nakadate T. Yamamoto S, Sigumura T. Inhibition of 12-0-tetradecanoylphorbol-l 3-acetate induced tumour promotion and ornithine decarboxylase by quercertin: possible inolvement of lipoxygenase inhibition. Carcinogenesis 1983; 4: 1301-5
20. Fujiki H. Horiuchi T. Yamashita K et al. Inhibition of tumour promotion by flavonoids. Pro0 Clin Biochem Res 1986: 213: 429-40
21. Andersson S. Berman DM. Jenkins EP, Russell DW. Deletion of steroid 5ot-reductase -2 gene in male pseudohermaphroditism. Nature 1991: 354: 159-61
22. Jenkins EP. Hsieh C-L, Milatovich A et al. Characterization and chromosomal mapping of human steroid 5a-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 1991: 11: 1102-12
23. Thigpen A. Davis DL, Milatovich A et al. Molecular genetics of steroid 5cx-reductase 2 deficiency. J Clin Invest 1992: 90: 799-809
24. lehle C. Delos S. Guirou O. Täte R. Raynaud J-P, Martin P-M. Human prostatic steroid 5ocreductase isoforms-a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995; 54: 273-9
25. Zahradnik HP. Schulfahrt R, Schoening R. Ebbinghaus KD. Dunzendorfer U. Prostaglandin content in prostate adenomas following treatment with a sterol. Fortschriftte der Medizin 1980: 98: 69-72
26. Ebbinghaus KD. Baur MP. Ergebnisse einer Doppleblinderstudie über die Wirksamkeit eined Medikamentes zur konservativen Behandlung des Prostataadenomas. Z All Med 1977; 53: 1054-8
27. Kadow C. Abrams PH. A double blind trial of the effect of beta-sitosteryl glucoside (WA 184) in the treatment of benign prostatic hyperplasia. Eur Urol 1986: 12: 187-9
28. Schneider H-J. Conservative treatment of benign prostatic hyperplasia (BPH). Results of a multi-centre study. Z All Med 1986; 62: 1069-72
29. Longo R. Tira S. Constituents of Pijgewn africanum bark. Planta Medica 1981: 42: 195-6
30. Donkervoort T. Sterling A, van Ness J. Donker PJ. A clinical and urodynamic study of Tadenan in the treatment of benign prostatic hypertrophy. Eur Urol 1977: 3: 218-25
31. Barlet A. Aibrecht ]. Aubert A et al. Efficacy of Pygenm africanwn in the treatment of micturitional disorders due to benign prostatic hyperplasia. Evaluation of objective and subjective parameters. Weiner Klinische Wochenschrift 1990: 22
32. Sultan C. Terraza A. Devillier C et al. Inhibition of androgen metabolism and binding by a liposterolic extract of Serenoa repens in human foreskin in fibroblasts. J Steroid Biochem Mol Biol 1984: 20: 2041-8
33. Briley M, Carilla E, Fauran F. Permixon, a new treatment for benign hyperplasia, acts directly at the cytosolic androgen receptor in rat prostate. Br }Pharmacol 1983: 79: 327-36
34. Carilla E, Briley M, Fauran F. Sultan Ch. Duvilliers C. Binding of Permixon. a new treatment for prostatic benign hyperplasia to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem Mol Biol 1984; 20: 521-3
35. Delos S. lehle C. Martin PM. Raynaud JP. Inhibition of the activity of basic 52-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 1994: 48: 347-52
36. Delos S. Carsol J-L. Ghazarossian E. Raynaud J-P. Martin P-M. Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts J Steroid Biochem Mol Biol 1996: in press
37. DiSilverio F. D'Eramo G. Lubrano C et al. Evidence that Serenoa repens extract displays an anti-estrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Ural 1992: 21: 309-14
38. Ragab A. Ragab-Thomas JMF. Delhom A et al. Effects of Permixon on phospholipase A2 activity and on arachidonic acid metabolism in cultured prostatic cells. In DiSilverio F. Steg A. eds., Trends in Bladder Cancer Chemotherapy. Xew Trends in BPH Etiopathogenesis. Acta Medica Roma. 1988: 1: 293-6
39. Champault G. Patel JC. Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in BPH. Br J Clin Pharmacol 1984: 18: 461-2
40. Cukier J. Ducassou J. Le Guillou M. Eeriche A, Eobel B, Toubol J. Permixon versus placebo-résultats d'une 'etude multicentrique. Comptes Rend Therapeut Pharmacol Clin 1985; 4: 15-21
41. Reece-Smith H. Memon A, Smart CJ, Dewbury K. The value of Permixon in benign prostatic hypertrophy. Br J Urol 1986; 58: 36-40
42. Descotes JE. Rambeaud JJ, Deschaseaux P. Faure G. Placebocontrolled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995: 5: 291-7
43. Carraro J-C. Raynaud J-P. Koch G et al. Comparison of Phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomised international study of 1098 patients. Prostate 1996: in press
44. Bach D. Medikamentöse Eangzeitbehandlung der BPHErgebnisse einewr prospektiven 3 jahres-studie mit dem Sabalextract IDS 89. Strogen S. Urologe \B] 1995: 35: 178-83
45. Stoner E and members of the Finasteride Study Group. Three year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284-94
46. Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic properties and therapeutic potential in benign prostatic hyperplasia. Drug & Ageing 1993; 3: 258-77
47. Weier H, Kreig M. Intraprostatic enzyme activities after 3 months treatment with the Sabal Extract IDS 89 (Strogen) or placebo. 1994; VInternational SymposiumPerspectives in the Drug Treatment of BPH (Abstr)
48. Ask-Upmark E. Die behandlung der prostatitis. Z Urol 1963; 56: 113-6
49. Takeuchi H, Yamauchi A, Ueda T, Hiraga S. Quantitative evaluation on the effectiveness of Cernilton on benign prostatic hypertrophy. Acta Urol Jap 1981; 3: 317-27
50. Becker H, Ebeling L. Konservative thérapie der benignen prostata-hyperplasie (BPH) mit Cernilton. Urologe (B) 1988; 28: 301-6
51. Buck AC, Cox R, Rees RWM, Ebeling L, John A. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton. Br J Urol 1990; 66: 398-404
52. Kimura M, Kimura I, Nakase K, Sonobe T, Mori E. Micturition activity of pollen extract: contractile effects on bladder and inhibitory effects on urethral smooth muscle of mouse and pig. Planta Medica 1986; 2: 148-51
53. Nakase S, Takenaka K, Hamanaka T, Kimura M. Effects of Cernilton pollen extract on the urethral smooth muscle and diaphragmatic neuromuscular specimen. Folio Pharmacol Japan 1988; 91: 385-92
54. Ito R, Ishii M, Yamashita S et al. Antiprostatic hypertrophie action of Cernilton pollen-extract. Pharmacometrics 1986; 31: 1-11
55. Tun S, Krieg M. Alterations in the intraprostatic hormonal metabolism by the pollen extract Cernilton. In Vahlensieck W, Rutishauser G, eds, Benign Prostatic Disease. Stuttgart: Thieme Medical Publishers, 1992: 109-14
56. Habib FK, Ross M, Lewenstein A, Zhang X, Jaton JC. The identification of a prostate inhibitory substance in a pollen extract. Prostate 1995; 26: 133-9
57. Caine M. Alpha-adrenergic blockers for the treatment of BPH. Urol Clin North Am 1990; 17: 641
58. Grasset D. Le Pygeum Africanum dans le traitement symptomatique de l'HPB. 1989: 191-8
59. Carbin B-E, Larson B, Lindahl 0. Treatment of benign prostatic hyperplasia with phytosterols. Br ] Urol 1990; 66: 639-41